## [1] "DADesign"
A logistic log normal model will describe the relationship between dose and toxicity: \[ p(Tox | d) = f(X = 1 | \theta, d) = \frac{e^{\alpha + \beta \cdot log(d/d_{ref})}}{1 + e^{\alpha + \beta \cdot log(d/d_{ref})}} \]where dref denotes a reference dose.
The prior for θ is given by\[ \boldsymbol\theta = \begin{bmatrix}\alpha \\ log(\beta)\end{bmatrix}\sim N \left(\begin{bmatrix}-0.85 \\ 1.00\end{bmatrix} , \begin{bmatrix} 1.00 & -0.50 \\ -0.50 & 1.00\end{bmatrix} \right) \]
The reference dose will be 56.00.
No participants are yet evaluable.
The dose grid is 0.1, 0.5, 1, 1.5, 3, 6, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 and 80.
To protect the welfare of individual participants, the rate of enrolment within each cohort will be restricted.
For all cohorts:
Before the next cohort can open, all participants in the current cohort must have been followed up for at least 7 days and at least one participant must have been followed up for at least 7 days.
If either of the following rules are TRUE:
P(0.2 ≤ prob(DLE | NBD) ≤ 0.35) ≥ 0.5: If the probability of toxicity at the next best dose is in the range [0.20, 0.35] is at least 0.50.
≥ 50 patients dosed: If 50 or more participants have been treated.
| Min | Max | Increment |
|---|---|---|
| 0 | 20 | 1.00 |
| 20 | Inf | 0.33 |
Placebo will not be administered in the trial.
The dose recommended for the next cohort will be chosen in the following way. First, doses that are ineligible according to the increments rule will be discarded. Next, any dose for which the mean posterior probability of toxicity being in the overdose range - (0.35, 1] - is 0.25 or more will also be discarded. Finally, the dose amongst those remaining which has the highest chance that the mean posterior probability of toxicity is in the target toxicity range of 0.2 to 0.35 (inclusive) will be selected.
| Lower | Upper | Cohort size |
|---|---|---|
| 0 | 30 | 1 |
| 30 | Inf | 3 |
| Lower | Upper | Cohort size |
|---|---|---|
| 0 | 1 | 1 |
| 1 | Inf | 3 |
The starting dose is 3.